![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication May 17, 2004.
Revised October 12, 2004.
Accepted for publication October 14, 2004.
The human B1 bradykinin receptor is an inducible and constitutively active G protein-coupled receptor that is involved in the inflammatory and pain responses to injury. Here, we investigated the role of B1 receptor homo-oligomerization in cell surface receptor expression. B1 receptors tagged with either the FLAG or hemagglutinin epitope were monitored immunologically and by radioligand binding, biotinylation, and phosphoinositide hydrolysis in human embryonic kidney 293 cells. Selective immunoprecipitation, immunoblotting, and immunoelectron microscopy with epitope-specific antibodies together provided evidence for constitutively formed cell surface receptor homo-oligomers. Truncation of the receptor from the N- and C-terminal ends indicated that the epitope for oligomerization appears to be located between Leu26 on top of transmembrane helix 1 and Val71 at the bottom of helix 2. A receptor construct terminating at Asp134 at the bottom of helix 3, B1stop135, was expressed in the cell. Interestingly, this construct behaved as a dominant-negative mutant by competitively preventing formation of intact B1 receptor homo-oligomers, and redistributing B1 receptors from the cell surface to a common intracellular compartment. In contrast, expression of a construct containing the residues downstream of Asp134, B1del(2-134), was inactive in this regard. Together, these results are consistent with a mechanism where constitutive B1 receptor homo-oligomerization is required for expression of receptors on the cell surface and subsequent constitutive receptor signaling. This may be a novel mechanism by which the cell regulates the presentation of this constitutively highly active receptor at various stages of injury.
Key words:
Bradykinin, IP3/DAG, Receptor synthesis/trafficking, Structure determinations, Receptor binding studies
This article has been cited by other articles:
|
|
 |
|
  X. Zhang, F. Tan, Y. Zhang, and R. A. Skidgel Carboxypeptidase M and Kinin B1 Receptors Interact to Facilitate Efficient B1 Signaling from B2 Agonists J. Biol. Chem., March 21, 2008; 283(12): 7994 - 8004. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ehrenfeld, C. Millan, C. E. Matus, J. E. Figueroa, R. A. Burgos, F. Nualart, K. D. Bhoola, and C. D. Figueroa Activation of kinin B1 receptors induces chemotaxis of human neutrophils J. Leukoc. Biol., July 1, 2006; 80(1): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Fortin, E. K. Dziadulewicz, L. Gera, and F. Marceau A Nonpeptide Antagonist Reveals a Highly Glycosylated State of the Rabbit Kinin B1 Receptor Mol. Pharmacol., April 1, 2006; 69(4): 1146 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
